Drug Discovery Today 2013 v.18 №13-14

London, UK.: Elsevier. — 92 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Can emerging drug classes improve R&D productivity?
Christoph Meier, Sarah Cairns-Smith, Ulrik SchulzeInto the valley of death: research to innovation
John Hudson, Hanan F. KhazraguiChallenges and opportunities for oncology biomarker discovery
Avisek Deyati, Erfan Younesi, Martin Hofmann-Apitius, Natalia NovacGastrointestinal weight-loss surgery: glimpses at the molecular level
Johannes M. Freudenberg, Neetu Rajpal, James M. Way, Michal Magid-Slav, Deepak K. RajpalSclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
Martyn K. Robinson, John Caminis, Mary E. BrunkowCompound promiscuity: what can we learn from current data?
Ye Hu, Jürgen BajorathInteractive design of generic chemical patterns
Karen T. Schomburg, Lars Wetzer, Matthias RareyConsidering the impact drug-like properties have on the chance of success
Iskander Yusof, Matthew D. SegallMolecular determinants of drug–receptor binding kinetics
Albert C. Pan, David W. Borhani, Ron O. Dror, David E. ShawBiodiversity of small molecules – a new perspective in screening set selection
Paula M. Petrone, Anne Mai Wassermann, Eugen Lounkine, Peter Kutchukian, Benjamin Simms, Jeremy Jenkins, Paul Selzer, Meir GlickCollaborative virtual organisation and infrastructure for drug discovery
Barry Hardy, Roman Affentranger